Posted by Michael Wonder on 04 Oct 2023
Pegunigalsidase alfa for the treatment of patients with Fabry disease
4 October 2023 - NICE has published evidence-based recommendations on the use of pegunigalsidase alfa (Elfabrio) for the treatment of adults with Fabry disease.
Pegunigalsidase alfa is recommended as an option for the treatment of adults with treating Fabry disease (also known as alpha-galactosidase deficiency).
